The global intestinal fistula treatment market is expected to be valued at US$ 26.64 Billion in 2023. With the continuous improvements in drugs and biotechnology, the overall demand for Intestinal Fistula Treatment is projected to grow at a CAGR of 5.8% between 2023 and 2033, totaling around US$ 46.82 Billion by 2033.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value for Intestinal Fistula Treatment in 2023 | US$ 26.64 Billion |
| Projected Market Value for Intestinal Fistula Treatment in 2033 | US$ 46.82 Billion |
| Global Growth Rate (2023 to 2033) | CAGR of 5.8% |
According to the analysis of Future Market Insights, factors such as a rise in the inflammatory bowel disease (IBD) patient pool, increase in the prevalence of Crohn’s disease, approval of new biologic drugs, novel drugs pipeline, and increase in demand for application of intestinal fistula treatment in developing countries are expected to augment the growth of the intestinal fistula treatment market.
Reimbursement plans introduced by the leading players to cushion healthcare expenditure will lead to positive sentiment among patients toward effective treatment. Growth in investments in the treatment of intestinal fistula is also anticipated to help achieve high ROI, as physicians tend to prescribe these drugs for the treatment of moderate to severe intestinal fistula. In addition, the development of anti-adhesion molecules is likely to propel the adoption of integrin antagonists.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for intestinal fistula treatment is projected to increase at a CAGR of 5.8% during the forecast period between 2023 and 2033, reaching a total of US$ 46.82 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3.2%. According to Future Market Insights, a market research and competitive intelligence provider, the Intestinal Fistula Treatment market was valued at US$ 25.18 Billion in 2022.
The global rise in the prevalence of intestinal fistula is driving the growth of the intestinal fistula treatment market. The major cause of the disease includes inflammatory bowel diseases, which result in long-term chronic inflammation of the gastrointestinal (GI) tract without any known cause. Factors such as innovations in product development, approval of drugs, and rising inclination toward the use of biologic and biosimilar drugs are expected to boost the revenue share of intestinal fistula treatment during the forecast period. Growth in sales of intestinal fistula drugs through online, retail, and hospital pharmacies is helping companies generate more revenues. For instance, in December 2019, the FDA approved two biosimilars - adalimumab and infliximab - for the treatment of Ulcerative Colitis.
Biopharmaceutical companies have made significant investments in Research and Development activities. Large numbers of pipeline products are in different stages of clinical approvals, which are likely to commercialize over the analysis period. According to a report, around 2.5 million people in the USA suffered from inflammatory bowel disease in 2020. The prevalence of IBD among the USA population is expected to rise to around 3.5 million by 2030. Similarly, data suggest that the incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing in Europe; around 0.2% of the population of Europe suffered from IBD in 2020. This in turn is anticipated to accelerate market growth in the forthcoming years.
Increasing focus on Research and Development for the Treatment of Intestinal Fistula to Fuel the Market Growth
Technological development, such as the use of single-cell RNA sequencing, is helping healthcare professionals in the treatment of intestinal fistula treatment. High-dimensional technologies such as single-cell RNA sequencing and mass cytometry have been performed on the intestinal specimens collected from patients suffering from Crohn’s disease or ulcerative colitis. Several benefits of the single-cell RNA sequencing analysis used to understand the molecular basis of the disease include the development of novel therapeutic approaches, optimizing the individual medicines, and preventing the disease.
For instance, in August 2020, The University of California and VA San Diego Healthcare System (VASDHS) used transcriptomic and antigen receptor sequencing strategies to characterize tissue and immune cell features in individuals with or without ulcerative colitis. These advancements in technology provide an unusual view of immune cell networks in health and disease. These factors are expected to escalate the growth of the intestinal fistula treatment market during the forecast period.
Rise in Awareness Regarding Intestinal Fistula to Accelerate the Market Growth
There are numerous factors that are responsible for the increasing prevalence of intestinal fistula treatment market, which are genetic predisposition, environmental triggers, and immune system disturbance, which all are results of Crohn’s Disease. The majority of the patients suffering from ulcerative colitis or Crohn’s disease have a family history of the disorder.
For instance, according to a research study conducted by Hopkins Medicine, about 10 to 15% of the patients suffering from Crohn’s disease have a family history of the disorder. Approximately 5 to 7% of the patients suffering from ulcerative colitis have a family history of the disorder.
Various government organizations are creating awareness about intestinal fistula by educating people about the symptoms, diagnosis, and treatments available for the condition. Hence, the rising awareness about the treatment options available and the increasing rate of disease diagnosis in developing countries are projected to support the market growth. Thus, the aforementioned factors are leading to increasing demand for drugs over the analysis period.
Principal Consultant
High Cost of Intestinal Fistula Drugs to Limit the Market Growth
The high treatment cost of the intestinal fistula, including the drug cost and other costs, reducing the number of patients undergoing treatment are expected to hinder the adoption of intestinal fistula treatment in patients. Additionally, the adoption of biologics is increasing to treat the disease, but the high costs associated with biologics treatment are limiting the market growth.
For instance, according to the National Center for Biotechnology Information (NCBI), the average annual cost of Adalimumab per person is about USD 12,343 in the United Kingdom In emerging countries, such as India, China, and Russia, there is a lack of reimbursement for intestinal fistula treatment, limiting the adoption of these drugs in the region. Hence, the high cost of medications for treating the disease and the lack of reimbursement policies in developing countries are anticipated to impede market growth in the near future.
Increase in Prevalence of Ulcerative Colitis in the Region to Fuel the Market Growth
The intestinal fistula treatment market in North America is expected to accumulate the highest market share of 45% in 2023. Factors such as the high prevalence and increase in the incidence of ulcerative colitis and Crohn’s disease in the USA and Canada, well-established healthcare infrastructure, and high risk of lifestyle-related factors are expected to augment the regional market growth during the forecast period.
Moreover, the strong product pipeline of key players is another major factor that is anticipated to fuel the market growth in the region. For instance, according to the National Center for Biotechnology Information (NCBI), the prevalence of inflammatory bowel disease in Canada will be over 0.75% in 2021. The region is expected to hold the highest CAGR of 5.7% during the forecast period.
Rising Awareness Regarding Available Treatment Options in the Region to Fuel the Market Growth
The intestinal fistula treatment market in the Asia Pacific is expected to accumulate the highest market share of 44% in 2023. The intestinal treatment market in China is anticipated to grow at a significant share over the analysis period. attributed to the factors such as an increase in the intestinal fistula patient pool and a rise in the focus of manufacturers on the development of novel therapeutics.
Additionally, factors including increasing awareness about available treatment options for the disease in the region and increasing approvals for the drugs for the treatment of the disease are also expected to fuel the regional market growth. For instance, in December 2021, Eisai Co., Ltd. and Gilead Sciences, Inc. agreed to the commercialization and distribution of filgotinib, an oral, JAK1 preferential inhibitor for indications of ulcerative colitis and Crohn's disease in Asia (South Korea, Taiwan, Hong Kong, and Singapore).
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Proton-Pump Inhibitors Segment to beat Competition in Untiring Market
On the basis of drug class, proton-pump inhibitors are likely to account for 45% of all drug sales. The segment is expected to augment at a CAGR of 5.7% over the analysis period. Growth is attributed to the factors such as the fact that the PPIs inhibit acid secretion, whether promoted by histamine, acetylcholine, or gastrin.
Moreover, PPIs work by irreversibly blocking the H+/K+ ATPase enzyme or the gastric proton pump, which is found within the parietal cells of the stomach and is the final step of acid production. All these factors are expected to stimulate the segment’s growth during the forecast period.
Hospital Pharmacies account for the bulk of all Intestinal Fistula Treatment Medication Sales
Based on distribution channels, hospital pharmacies are expected to account for 46% of intestinal fistula treatment medication sales in 2023 and are expected to grow at a 5.6% CAGR until 2033. Growth is attributed to the fact that most of the major intestinal fistula treatment drugs and products are prescription products, which are available in hospital pharmacies.
Furthermore, the segment dominated the market with a significant share, attributed to reimbursement policies in developing countries, which cover the high cost of these drugs. For instance, according to Baylor Scott & White, in the USA, approximately 45% of the costs are covered by the pharmacy, including injectable drugs and others.
Intestinal Fistula Treatment Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,
Prominent players in the intestinal fistula treatment market are:
Recent Developments:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.8% from 2023 to 2033 |
| Market Value in 2023 | US$ 26.64 Billion |
| Market Value in 2033 | US$ 46.82 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available upon Request |
Asia Pacific is expected to accumulate a market share of 44% in 2023.
From 2018 to 2022, the market registered a CAGR of 5.8%.
The market is likely to register a 5.8% CAGR Until 2033.
The industry is expected to reach US$ 46.82 billion in 2033.
North America is expected to accumulate a high market share of 45% in 2023.
1. Executive Summary | Intestinal Fistula Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Billion) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Billion) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Billion) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Anticholinergic
5.3.2. Proton-pump Inhibitors
5.3.3. H2 Blockers
5.3.4. Antidiarrheals
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Billion) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Parenteral
6.3.3. Rectal
6.3.4. Transdermal
6.3.5. Intravenous
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Billion) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Clinical Pharmacies
7.3.3. Drug Stores
7.3.4. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Billion) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Billion) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa(MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of Middle East and Africa(MEA)
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Drug Class
14.1.2.2. By Route of Administration
14.1.2.3. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Drug Class
14.2.2.2. By Route of Administration
14.2.2.3. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Drug Class
14.3.2.2. By Route of Administration
14.3.2.3. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Drug Class
14.4.2.2. By Route of Administration
14.4.2.3. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Drug Class
14.5.2.2. By Route of Administration
14.5.2.3. By Distribution Channel
14.6. United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Drug Class
14.6.2.2. By Route of Administration
14.6.2.3. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Drug Class
14.7.2.2. By Route of Administration
14.7.2.3. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Drug Class
14.8.2.2. By Route of Administration
14.8.2.3. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Drug Class
14.9.2.2. By Route of Administration
14.9.2.3. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Drug Class
14.10.2.2. By Route of Administration
14.10.2.3. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Drug Class
14.11.2.2. By Route of Administration
14.11.2.3. By Distribution Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Drug Class
14.12.2.2. By Route of Administration
14.12.2.3. By Distribution Channel
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Drug Class
14.13.2.2. By Route of Administration
14.13.2.3. By Distribution Channel
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Drug Class
14.14.2.2. By Route of Administration
14.14.2.3. By Distribution Channel
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Drug Class
14.15.2.2. By Route of Administration
14.15.2.3. By Distribution Channel
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Drug Class
14.16.2.2. By Route of Administration
14.16.2.3. By Distribution Channel
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Drug Class
14.17.2.2. By Route of Administration
14.17.2.3. By Distribution Channel
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Drug Class
14.18.2.2. By Route of Administration
14.18.2.3. By Distribution Channel
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Drug Class
14.19.2.2. By Route of Administration
14.19.2.3. By Distribution Channel
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Drug Class
14.20.2.2. By Route of Administration
14.20.2.3. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Livealth BioPharma
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Boehringer Ingelheim International GmbH
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Pfizer
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Apsolabs
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. AstraZeneca
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Pipelinepharma
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Astellas Pharma Inc
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Caspian Tamin Pharmaceutical Company
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Eli Lilly
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. GlaxoSmithKline
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Intestinal Fistula Treatment Market
